Oncology Pipeline

Track our discoveries and stages of clinical development.

Mechanism of action for our commercial and clinical assets

TRABECTEDIN

LURBINECTEDIN

PLITIDEPSIN

ECUBECTEDIN

TRABECTEDIN

Trabectedin, also known as ecteinascidin 743 or ET-743l, or commercially where it is approved as Yondelis® is a synthetic compound derived from the colonial sea squirt Ecteinascidia turbinata.

Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

LURBINECTEDIN

Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds.

Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

PLITIDEPSIN

Plitidepsin, also known as PM90001, or Aplidin® in Australia where it is approved for multiple myeloma, is a synthetic compound originally inspired by ascidian Aplidium albicans, a tunicate.

Its mechanism of action is as an inhibitor of the eukaryotic translation eEF1A. In cancer cells this ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.

ECUBECTEDIN

Ecubectedin, also known as PM14, is a synthetic analog from the medicinal chemistry program of lurbinectedin.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes

TRABECTEDIN

TRABECTEDIN

Trabectedin, also known as ecteinascidin 743 or ET-743l, or commercially where it is approved as Yondelis® is a synthetic compound derived from the colonial sea squirt Ecteinascidia turbinata.

Trabectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

LURBINECTEDIN

LURBINECTEDIN

Lurbinectedin, also known as PM01183, or commercially where approved as Zepzelca® is an analogue of a similar natural compound ET-736 with characteristics that make it similar but different to its parent compounds.

Lurbinectedin inhibits active transcription of protein-coding genes through binding to promoters and irreversibly stalling elongating RNA polymerase II on the DNA template, thereby leading to double-stranded DNA breaks and apoptosis.

PLITIDEPSIN

PLITIDEPSIN

Plitidepsin, also known as PM90001, or Aplidin® in Australia where it is approved for multiple myeloma, is a synthetic compound originally inspired by ascidian Aplidium albicans, a tunicate.

Its mechanism of action is as an inhibitor of the eukaryotic translation eEF1A. In cancer cells this ultimately leads to cell-cycle arrest, growth inhibition and induction of apoptosis via multiple pathway alterations.

ECUBECTEDIN

ECUBECTEDIN

Ecubectedin, also known as PM14, is a synthetic analog from the medicinal chemistry program of lurbinectedin.

Ecubectedin is a compound that acts by specifically inhibiting RNA synthesis and active transcription of protein-coding genes

We´re a unique kind of pharma company

We are inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. We intend to continue to be the world leader in marine medicinal discovery, development and innovation.

  • Global marine expeditions finding new organisms
  • Screen for anti-cancer properties
  • Isolate, refine, synthesize, prioritize
  • Robust in vitro and in vivo testing

"PharmaMar was the first company in the world to develop a marine-based cancer drug from discovery through to commercialization."

Luis Mora

Managing Director

A team of experts

We are a multi-disciplinary team of biologists, chemists, clinicians, engineers, computer technicians, lab professionals, biostatisticians and more, all working tirelessly towards one goal; to improve the healthcare outcomes of people afflicted with serious diseases.

  • More than 400 employees
  • 20 different nationalities; 15 languages
  • 65% university graduates and 18% PhD’s

Meet the team ->

0.3767 seconds.